Search
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational_PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. … Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.
Categories: Cytochrome P-450 CYP2B6 Inducers, Heterocyclic Compounds, 1-RingSynonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-Benfluorex
go.drugbank.com/drugs/DB09022ApprovedWithdrawnBenfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It was patented and manufactured by a French pharmaceutical company Servier. … The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.
Categories: Drugs Used in DiabetesRemimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigationalRemimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. … [A214857] These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed.
Categories: Heterocyclic Compounds, 2-RingAS-8112
go.drugbank.com/drugs/DB09207ExperimentalAS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3. … It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use.
Categories: Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, 1-RingPhenylacetic acid
go.drugbank.com/drugs/DB09269ApprovedBecause it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China. … Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor.
Categories: Ammonium Ion Binding ActivitySynonyms: ANTINEOPLASTON AS 2-1 COMPONENT PHENYLACETIC ACID, α-toluic acidBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnIt is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). … It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 1-PYRROLIDENEETHANAMINE, .BETA.-((2-METHYLPROPOXY)METHYL)-N-PHENYL-N-(PHENYLMETHYL)-, 1-(2-(N-BENZYLANILINO)-1-(ISOBUTOXYMETHYL)ETHYL)-PYRROLIDINEOXI-4503
go.drugbank.com/drugs/DB05143InvestigationalOXI-4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA). … Preclinical studies have demonstrated that OXI-4503 has (i) single-agent activity against a range of xenograft tumor models; and (ii) synergistic or additive effects when incorporated in various combination
Synonyms: Combretastatin A-1 bis(phosphate)Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalIn clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo [A32046]. … This allows less frequent dosing and a lower daily dose with improvement in tolerability [A32043].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: D6 tetrabenazine, D6-tetrabenazinePolatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigationalPolatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesFerrous ascorbate
go.drugbank.com/drugs/DB14490ApprovedWithdrawnSynonyms: Iron(2+) L-ascorbate, L-Ascorbic acid, iron complexCategories: Compounds used in a research, industrial, or household setting